Arcutis Biotherapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Arcutis Biotherapeutics

12/08/2024 22:45

* Arcutis Biotherapeutics Inc  ARQT.OQ   ARQT.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 14 for the period ending January 1 0001
    * The Westlake Village California-based  company is expected
to
report a 460.3% increase in revenue to $29.08 million from $5.19
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Arcutis Biotherapeutics
Inc is
for a loss of 52 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arcutis
Biotherapeutics Inc is $19.00​, above​ its last closing price
of $9.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.71       -0.73      -0.32     Beat    56.2
 Jan. 1 2024   -0.75       -0.77      -0.72     Beat    7.1
 Sep. 30 2023  -0.70       -0.86      -0.73     Beat    14.9​
 Jun. 30 2023  -1.25       -1.25      -1.16     Beat    7.2
 ​​Mar.        -1.26       -1.28      -1.31     Missed  -2
 31 2023                                                
 Dec. 31 2022  -1.41       -1.42      -1.18     Beat    17.1​
 Sep. 30 2022  -1.70       -1.67      -1.89     Missed  -13.2
 Jun. 30 2022  -1.41       -1.43      -1.31     Beat    8.6
 This summary was machine generated August 12 at 21:45 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)